Tavafos 150 mg is a Product of the Generic Fostamatinib Disodium Hexahydrate

What Is Tavafos 150 mg Indications and Uses?

Tavafos 150 mg (Fostamatinib Disodium Hexahydrate) is indicated for Chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.

Pharmacology (Source, Chemical and Physical Composition) Of Tavafos 150 mg

Tavafos 150 mg (Fostamatinib Disodium Hexahydrate) is a tyrosine kinase inhibitor medication for the treatment of chronic immune thrombocytopenia (ITP). Fostamatinib blocks the activity of the enzyme spleen tyrosine kinase (SYK). This enzyme is involved in stimulating parts of the immune system. By blocking SYK's activity, Fostamatinib reduces the immune system's destruction of platelets, so allowing the platelet count to rise, which reduces the likelihood of excessive bleeding.

Dosage And Administration of Tavafos 150 mg

The recommended starting dose of Tavafos 150 mg (Fostamatinib Disodium Hexahydrate) is 100 mg twice daily. After initiating Fostamatinib, the dose can be increased to 150 mg twice daily after 4 weeks based on platelet count and tolerability. A daily dose of 300 mg daily must not be exceeded. Missed dose: In the case of a missed dose of Fostamatinib, patients should take their next dose at its regularly scheduled time. Discontinuation: Treatment with Fostamatinib should be discontinued after 12 weeks of Fostamatinib therapy if the platelet count does not increase to a level sufficient to avoid clinically important bleeding.

Drug Interactions of Tavafos 150 mg

Concomitant use of Rifampicin, a strong CYP3A4 inducer (600 mg once daily for 8 days) with a single dose of 150 mg Tavafos 150 mg (Fostamatinib Disodium Hexahydrate) decreased R406 AUC by 75% and Cmax by 59%. Concomitant use of Tavafos with strong CYP3A4 inducers decreases exposure to R406, which may result in reduced efficacy. Therefore, concomitant use of Tavafos with strong CYP3A4 inducers is not recommended. Concomitant use of Tavafos with strong CYP3A4 inhibitors increases exposure to R406 (the major active metabolite), which may increase the risk of adverse reactions. The patient should be monitored for toxicities of Tavafos that may require dose reduction when given concurrently with strong CYP3A4 inhibitors.

Side Effects of Tavafos 150 mg

Allergic reactions Abdominal pain Diarrhea

Precautions And Warnings for Tavafos 150 mg

Hypertension : Monitor blood pressure every 2 weeks until stable, then monthly. Manage hypertension using standard antihypertensive treatment and, if needed, interrupt, reduce or discontinue Tavafos 150 mg (Fostamatinib Disodium Hexahydrate) Hepatotoxicity : Monitor LFTs monthly. If LFT levels are elevated, interrupt, reduce or discontinue Tavafos Diarrhea : Manage diarrhea with supportive measures. If diarrhea becomes severe, interrupt, reduce or discontinue Tavafos Neutropenia : Monitor ANC monthly, and for infection. If neutrophil count decreases below 1.0 x 109/L, interrupt, reduce or discontinue Tavafos Embryo-Fetal Toxicity : Tavafos can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception

Use During Pregnancy and Lactation

Tavafos 150 mg (Fostamatinib Disodium Hexahydrate) is contraindicated during pregnancy.

Therapeutic Class

Tyrosine Kinase Inhibitor

Storage Conditions of It

For indications and dosage please see the package insert. To be dispensed only by or on the prescription of a registered physician. Store in a cool (below 30°C), dry place and away from light. Keep out of the reach of children. Pack Image: Tavafos 150 mg Tablet Thanks for using MedEx! How would you rate your experience so far?